| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 10 | 2023 | 2027 | 1.180 |
Why?
|
| Liver Neoplasms | 10 | 2023 | 4557 | 0.990 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2021 | 393 | 0.870 |
Why?
|
| Health Services for Transgender Persons | 1 | 2021 | 1 | 0.830 |
Why?
|
| Sex Reassignment Procedures | 1 | 2021 | 19 | 0.820 |
Why?
|
| Gender Identity | 1 | 2021 | 75 | 0.790 |
Why?
|
| Transgender Persons | 1 | 2021 | 55 | 0.760 |
Why?
|
| Patient Transfer | 1 | 2021 | 137 | 0.740 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 4844 | 0.730 |
Why?
|
| Neoadjuvant Therapy | 6 | 2019 | 4975 | 0.730 |
Why?
|
| Adenocarcinoma | 8 | 2020 | 7789 | 0.720 |
Why?
|
| Veterans | 6 | 2024 | 1641 | 0.720 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 294 | 0.640 |
Why?
|
| Stomach Neoplasms | 3 | 2021 | 2278 | 0.630 |
Why?
|
| Exercise Therapy | 1 | 2021 | 288 | 0.630 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 792 | 0.590 |
Why?
|
| Cancer Survivors | 2 | 2021 | 650 | 0.580 |
Why?
|
| Gastrectomy | 2 | 2021 | 451 | 0.580 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 918 | 0.560 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 105 | 0.530 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 83 | 0.530 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 135 | 0.510 |
Why?
|
| Natural Language Processing | 1 | 2016 | 119 | 0.510 |
Why?
|
| Lymph Nodes | 5 | 2019 | 2967 | 0.500 |
Why?
|
| Fatigue | 1 | 2021 | 1239 | 0.500 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 3890 | 0.450 |
Why?
|
| Hospitals | 3 | 2020 | 485 | 0.390 |
Why?
|
| Databases, Factual | 3 | 2018 | 2218 | 0.380 |
Why?
|
| HIV Infections | 1 | 2023 | 2134 | 0.370 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 1202 | 0.350 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 213 | 0.340 |
Why?
|
| Physician's Role | 1 | 2011 | 238 | 0.330 |
Why?
|
| Electronic Health Records | 2 | 2016 | 929 | 0.300 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 13658 | 0.290 |
Why?
|
| Communication | 2 | 2022 | 876 | 0.280 |
Why?
|
| Aged | 25 | 2024 | 70117 | 0.280 |
Why?
|
| Retrospective Studies | 16 | 2023 | 37905 | 0.270 |
Why?
|
| Primary Health Care | 1 | 2011 | 787 | 0.250 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 600 | 0.250 |
Why?
|
| Algorithms | 1 | 2016 | 3890 | 0.250 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 4988 | 0.250 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5767 | 0.240 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 14289 | 0.240 |
Why?
|
| Esophagectomy | 2 | 2018 | 911 | 0.230 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 64 | 0.220 |
Why?
|
| United States | 12 | 2021 | 15433 | 0.220 |
Why?
|
| Middle Aged | 19 | 2024 | 86204 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 2231 | 0.220 |
Why?
|
| Male | 24 | 2021 | 123000 | 0.220 |
Why?
|
| Humans | 34 | 2024 | 261506 | 0.210 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 29902 | 0.210 |
Why?
|
| Frailty | 1 | 2024 | 113 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6207 | 0.190 |
Why?
|
| Female | 22 | 2021 | 141928 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 8865 | 0.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2015 | 421 | 0.170 |
Why?
|
| Emotions | 2 | 2021 | 562 | 0.170 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 1946 | 0.160 |
Why?
|
| False Negative Reactions | 1 | 2019 | 275 | 0.160 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 565 | 0.160 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 1390 | 0.150 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 42 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 15862 | 0.140 |
Why?
|
| Hospice Care | 1 | 2018 | 156 | 0.140 |
Why?
|
| Veterans Health | 1 | 2018 | 181 | 0.140 |
Why?
|
| Telemedicine | 1 | 2022 | 471 | 0.140 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 99 | 0.140 |
Why?
|
| Liver Cirrhosis | 2 | 2020 | 941 | 0.140 |
Why?
|
| Stomach | 1 | 2019 | 387 | 0.140 |
Why?
|
| Rectum | 1 | 2018 | 467 | 0.130 |
Why?
|
| Treatment Outcome | 9 | 2019 | 32848 | 0.130 |
Why?
|
| Adult | 10 | 2021 | 77950 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 3578 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 334 | 0.130 |
Why?
|
| Gallbladder Neoplasms | 1 | 2017 | 245 | 0.130 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2016 | 605 | 0.130 |
Why?
|
| Motor Activity | 1 | 2019 | 693 | 0.130 |
Why?
|
| Young Adult | 5 | 2021 | 21445 | 0.120 |
Why?
|
| Comorbidity | 2 | 2019 | 2352 | 0.120 |
Why?
|
| Esophageal Neoplasms | 2 | 2018 | 3168 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 333 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 348 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 2316 | 0.120 |
Why?
|
| Registries | 2 | 2019 | 2170 | 0.110 |
Why?
|
| Pancreatectomy | 1 | 2017 | 652 | 0.110 |
Why?
|
| Cohort Studies | 7 | 2021 | 9244 | 0.110 |
Why?
|
| Adolescent | 5 | 2021 | 31252 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2019 | 1529 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 493 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3719 | 0.110 |
Why?
|
| Palliative Care | 2 | 2018 | 2037 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 493 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1303 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 598 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 2083 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1225 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 5437 | 0.100 |
Why?
|
| Neoplasms | 3 | 2024 | 15193 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 10001 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 551 | 0.090 |
Why?
|
| Patient Care Management | 1 | 2011 | 94 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4892 | 0.090 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 98 | 0.090 |
Why?
|
| Outpatients | 1 | 2013 | 462 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2013 | 899 | 0.090 |
Why?
|
| Gait | 2 | 2021 | 165 | 0.080 |
Why?
|
| Perception | 1 | 2011 | 350 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 397 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2011 | 556 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 678 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1249 | 0.080 |
Why?
|
| Quinazolines | 1 | 2012 | 923 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 4971 | 0.070 |
Why?
|
| Terminally Ill | 1 | 2008 | 91 | 0.070 |
Why?
|
| Attitude to Death | 1 | 2008 | 100 | 0.070 |
Why?
|
| Quality of Life | 1 | 2021 | 4532 | 0.070 |
Why?
|
| Piperidines | 1 | 2012 | 1035 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2011 | 795 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2017 | 9180 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2008 | 465 | 0.060 |
Why?
|
| Fear | 2 | 2021 | 254 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 2341 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 4367 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2017 | 3341 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2011 | 1423 | 0.050 |
Why?
|
| Survival Rate | 3 | 2021 | 12221 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 5687 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 1000 | 0.050 |
Why?
|
| Prognosis | 1 | 2018 | 21713 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5061 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 10035 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 142 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 5159 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2884 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4298 | 0.040 |
Why?
|
| Attention | 1 | 2019 | 281 | 0.040 |
Why?
|
| Postural Balance | 1 | 2019 | 151 | 0.040 |
Why?
|
| Diplopia | 1 | 2017 | 66 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2012 | 11965 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2019 | 295 | 0.040 |
Why?
|
| Exercise | 1 | 2024 | 1183 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 2803 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 6869 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 237 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 829 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 1178 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 5319 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 181 | 0.030 |
Why?
|
| Dyspnea | 1 | 2017 | 416 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1559 | 0.030 |
Why?
|
| Independent Living | 1 | 2013 | 73 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 5047 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 10331 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 353 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1656 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 220 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 851 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 503 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 17523 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 11538 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1959 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 1099 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3981 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 980 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6100 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 18 | 0.020 |
Why?
|
| Existentialism | 1 | 2008 | 9 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4320 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 630 | 0.020 |
Why?
|
| New York | 1 | 2008 | 104 | 0.020 |
Why?
|
| Grief | 1 | 2008 | 29 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2013 | 524 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 15694 | 0.020 |
Why?
|
| Spirituality | 1 | 2008 | 129 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1533 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 3441 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 244 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 290 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1148 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2508 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 552 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 12926 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1054 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1021 | 0.010 |
Why?
|
| Family | 1 | 2008 | 736 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 2086 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2012 | 2295 | 0.010 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 3154 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 6682 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 14889 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 4757 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 12873 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 8873 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 59536 | 0.000 |
Why?
|